Dr. Christa Wirthumer-Hoche has been elected as the new chair of the Management Board of the European Medicines Agency (EMA).
Dr. Christa Wirthumer-Hoche has been elected as the new chair of the Management Board of the European Medicines Agency (EMA). The post is for a three-year period, and she succeeds Kent Woods, who stepped down as chair of the Board in December.
Wirthumer-Hoche has been head of the Austrian Medicines and Medical Devices Agency since October 2013, and has served as vice-chair of EMA’s Management Board since March 2015. She is also co-chair of the EU Network Training Center that was launched in January 2015 and has served as chair of EMA’s Active Substance Master File Working Group.
“As chair, my ambition is to ensure a strong partnership between EMA, the European Union national competent authorities and the European Commission to guarantee that EMA is able to fulfil its important role of safeguarding human and animal health in Europe,” said Wirthumer-Hoche, who holds a doctorate from the Technical University of Vienna and a diploma in chemistry and biochemistry.
The Management Board sets the EMA’s budget, approves the annual work program, and is responsible for ensuring that the agency works effectively and co-operates successfully with partner organizations across the EU and beyond.
In her statement dated October 19, 2015, Wirthumer-Hoche declared no conflicts of interest. Her replacement as the vice-chair has not been announced yet.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.